{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:12:15Z","timestamp":1761293535235,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.anl.2017.01.005","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T18:30:48Z","timestamp":1487788248000},"page":"724-728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The efficiency and adverse events of radiotherapy with cetuximab for Japanese head and neck cancer patients"],"prefix":"10.1016","volume":"44","author":[{"given":"Kazuhiro","family":"Hirasawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaku","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Takase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Agata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoaki","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anl.2017.01.005_bib0005","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer","volume":"349","author":"Forastiere","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2017.01.005_bib0010","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3109\/00016489.2014.913314","article-title":"Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas","volume":"134","author":"Tsukahara","year":"2014","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.anl.2017.01.005_bib0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2017.01.005_bib0020","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jjco\/hyt030","article-title":"Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck","volume":"43","author":"Okano","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.anl.2017.01.005_bib0025","first-page":"71","article-title":"Roles of chemotherapy in head and neck cancer","volume":"109","author":"Tsukahara","year":"2016","journal-title":"Practica OtoRhinolaryngol"},{"key":"10.1016\/j.anl.2017.01.005_bib0030","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s13691-014-0191-5","article-title":"A case of fatal interstitial pneumonia during treatment of radiotherapy plus cetuximab for patient with head and neck carcinoma","volume":"4","author":"Matsuyama","year":"2015","journal-title":"Int Cancer Conf J"},{"key":"10.1016\/j.anl.2017.01.005_bib0035","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.2005.01.2047","article-title":"Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm","volume":"24","author":"Urba","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2017.01.005_bib0040","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1586\/14737140.2013.829646","article-title":"Chemoselection: a paradigm for optimization of organ preservation in locally advanced larynx cancer","volume":"13","author":"Vainshtein","year":"2013","journal-title":"Expert Rex Anticancer Ther"},{"key":"10.1016\/j.anl.2017.01.005_bib0045","article-title":"NCCN clinical practice guidelines in oncology, head and neck cancers version I","author":"David","year":"2016","journal-title":"Natl Compr Cancer Netw"},{"key":"10.1016\/j.anl.2017.01.005_bib0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.critrevonc.2010.02.002","article-title":"Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma","volume":"77","author":"Wildiers","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.anl.2017.01.005_bib0055","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00280-014-2416-x","article-title":"The impact of dose\/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer","volume":"73","author":"Nakayama","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.anl.2017.01.005_bib0060","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/lary.23570","article-title":"Differential response rates to irradiation among patients with human papillomavirus positive and negative oropharyngeal cancer","volume":"123","author":"Chen","year":"2013","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anl.2017.01.005_bib0065","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s12885-016-2706-2","article-title":"Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis","volume":"16","author":"Huang","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.anl.2017.01.005_bib0070","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/annonc\/mdp573","article-title":"Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemotherapy in locally advanced head and neck cancer: a phase II randomized study","volume":"21","author":"Paccagnella","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anl.2017.01.005_bib0075","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1200\/JCO.2013.54.6309","article-title":"Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer","volume":"25","author":"Cohen","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2017.01.005_bib0080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomized phase 3 trial","volume":"14","author":"Haddad","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anl.2017.01.005_bib0085","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/annonc\/mdt461","article-title":"A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer","volume":"25","author":"Hitt","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anl.2017.01.005_bib0090","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s12885-016-2706-2","article-title":"Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis","volume":"16","author":"Huang","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.anl.2017.01.005_bib0095","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2015.63.1671","article-title":"Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial","volume":"34","author":"Magrini","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2017.01.005_bib0100","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","article-title":"Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer","volume":"21","author":"Mendelsohn","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2017.01.005_bib0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2005.06.022","article-title":"Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity","volume":"76","author":"Dittmann","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.anl.2017.01.005_bib0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.oraloncology.2015.12.001","article-title":"Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation","volume":"54","author":"Samuels","year":"2016","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2017.01.005_bib0115","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.oraloncology.2015.05.002","article-title":"Late toxicity after radical treatment for locally advanced head and neck cancer","volume":"51","author":"Taberna","year":"2015","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2017.01.005_bib0120","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","article-title":"Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study","volume":"31","author":"Lefebvre","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2017.01.005_bib0125","unstructured":"Pharmaceuticals and medical devices agency. Interview form: Erbitux. 2015, from Pharmaceuticals and medical devices agency website: http:\/\/www.info.pmda.go.jp\/go\/interview\/1\/380079_4291415A1021_2_1F."},{"key":"10.1016\/j.anl.2017.01.005_bib0130","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1097\/JTO.0b013e3182598abb","article-title":"Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer(NSCLC): an interim analysis of 3488 patients (POLARSTAR)","volume":"7","author":"Nakagawa","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.anl.2017.01.005_bib0135","first-page":"664","article-title":"lnterstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two PhaseIII trials (NEJ 002 and WJTOG 3405)","volume":"43","author":"Akamatsu","year":"2013","journal-title":"Jpn J Ciin Oncol"}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814616304576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814616304576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:33:10Z","timestamp":1759951990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814616304576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0385814616304576"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2017.01.005","relation":{},"ISSN":["0385-8146"],"issn-type":[{"type":"print","value":"0385-8146"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficiency and adverse events of radiotherapy with cetuximab for Japanese head and neck cancer patients","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2017.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}